论文部分内容阅读
fgl2凝血酶原酶是新近发现的凝血因子,主要表达于外周血T淋巴细胞、活化的内皮细胞和巨噬细胞等免疫活性细胞,其不依赖经典内、外源性凝血途径,可直接激活凝血酶原,启动凝血反应。近年来随着对fgl2凝血酶原酶日益关注,相关研究渗透到临床各专业,为阻断、延缓疾病的发生、发展和新药开发提供了靶向,为防治疾病带来新希望。该文将近几年fgl2凝血酶原酶在消化、呼吸、泌尿、心血管及风湿免疫系统等的临床应用基础研究做一综述,作为研究者进一步深入探索的启发和参考。
Fgl2 prothrombinase is a newly discovered clotting factor, mainly expressed in peripheral blood T lymphocytes, activated endothelial cells and macrophages and other immune cells, which do not rely on the classic, extrinsic coagulation pathway, can be directly activated coagulation Zymogen, start the clotting reaction. In recent years, with the growing concern about fgl2 prothrombinase, related research has penetrated into various clinical professions, which has provided a target for blocking and delaying the occurrence, development and development of new drugs and bringing new hope for the prevention and treatment of the disease. This article in recent years fgl2 prothrombinase enzymes in digestion, respiration, urinary, cardiovascular and rheumatic immune system and other clinical application of basic research to do a review, as researchers further explore the inspiration and reference.